最新ニュース Hologic (NASDAQ:HOLX) 株価情報

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Hologic Inc

Hologic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has fallen 5.41% since its last report. The company recently reported that it has 4.59 million shares sold short, which is 2.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732733111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hologic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 3.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

HOLX

Peering Into Hologic's Recent Short Interest

Hologic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has risen 5.03% since its last report. The company recently reported that it has 5.81 million shares sold short, which is 3.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730909726_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hologic has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 4.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Hologic's Recent Short Interest

Raymond James analyst Andrew Cooper maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and raises the price target from $93 to $95.

News

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Hologic, Raises Price Target to $95

Mizuho analyst Anthony Petrone maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $90 to $87.

Mizuho Maintains Outperform on Hologic, Lowers Price Target to $87

UBS analyst Elizabeth Garcia maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Neutral and raises the price target from $84 to $90.

UBS Maintains Neutral on Hologic, Raises Price Target to $90

RBC Capital analyst Conor McNamara maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and raises the price target from $86 to $89.

RBC Capital Maintains Sector Perform on Hologic, Raises Price Target to $89

JP Morgan analyst Casey Woodring maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Overweight and raises the price target from $92 to $94.

JP Morgan Maintains Overweight on Hologic, Raises Price Target to $94

WIIM

Hologic shares are trading lower. The company reported Q4 financial results.

Buybacks

Hologic Intends To Enter Into An Accelerated Share Repurchase Agreement For $250M Of The Company's Common Stock.

Guidance

Hologic Sees FY25 Adj. EPS $4.25-$4.35, Revenue $4.15B-$4.20B; Sees Q1 Adj. EPS $1.00-$1.03, Revenue $1.025B-$1.035B

Earnings

Earnings Beats

Hologic Q4 2024 Adj. EPS $1.01, Inline, Sales $987.900M Beat $976.688M Estimate

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of <a href="https://www.benzinga.com/topic/election-day">Election Day on Tuesday</a>. 
Vice President Kamala Harris holds a 1-point lead over ex-President Donald Trump, according to the New York Times national polling average; she has a 4-point lead among likely voters nationally, <a href="https://maristpoll.marist.edu/polls/u-s-presidential-contest-november-2024/">according to the latest PBS News/NPR/Marist poll</a>.
Betting markets, as tracked by the CFTC-regulated Kalshi, favor a Trump win at a 53% chance, <a href="https://www.benzinga.com/general/politics/24/11/41702729/harris-surges-in-prediction-markets-nabs-kalshi-lead-with-just-three-days-to-go">but with diminishing odds</a> compared to previous weeks. Also, the betting odds are susceptible to wild swings from so-called "whale" bettors, including one individual on Polymarket <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41463756/polymarket-to-review-user-base-in-light-of-whales-betting-millions-on-trump-election-win" target="_blank" rel="noreferrer noopener">who spent as much as</a> $43 million on a Trump victory.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41717129/polymarkets-all-time-leading-trader-bets-over-500-000-on-kamala-harris-slams-nate-silver-f">Polymarket&#8217;s All-Time Leading Trader Bets Over $500,000 On Kamala Harris, Slams Nate Silver For Including &#8216;Fake Poll&#8217; Data In Model</a>
&#8220;Neither candidate holds a meaningful edge in enough states to win 270 electoral votes. In the history of modern polling, there's never been a race where the final polls showed such a close contest,&#8221; said Nate Cohn, chief political analyst for the New York Times. 
The S&amp;P 500 slipped 0.2%, while the Dow dropped 0.6%, hitting its lowest intraday level since mid-September. In contrast, small-cap stocks in the Russell 2000 outperformed, rising 1%. The Nasdaq 100 also retreated, dipping below the 20,000 mark.
Treasury yields fell by nearly 10 basis points as investors scaled back positions linked to Trump&#8217;s inflationary policies, such as high tariffs and more expansionary fiscal measures. The dollar also weakened, down 0.5%.
The increasing likelihood of a Harris victory gave a boost to solar and renewable energy stocks, with the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) climbing 3.6%. 
Oil and gas stocks also gained, as crude prices surged 3% after OPEC+ postponed an anticipated production hike. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) jumped 3%, marking its largest single-day gain since late June.
Gold held steady at $2,740, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell over 1%, dropping below $68,000.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,230.95</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,715.31</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,978.22</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,807.92</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.1% to $570.22.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.5% to $418.44.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.2% to $486.77.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $221.27.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, rising 1.7%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.5%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), down 3.9%, </li>
<li>Constellation Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NYSE">CEG</a>), down 10.5%, </li>
<li>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), down 1.8%, </li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), down 0.4%, </li>
<li>Public Service Enterprise Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), down 5.9%, </li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), down 5.5%. </li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>), up 3.7%, </li>
<li>YUM China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>), up 7.9%, </li>
<li>Loews Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>), down 4.8%, </li>
</ul>
Stocks slated to report earnings after the close are Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) and Astera Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41702887/harris-takes-lead-in-red-state-iowa-in-shock-poll">Harris Takes Lead In Red State Iowa In Shock Poll</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Politics

Economics

Tech

ETFs

$BTC

ALAB

SPDR Dow Jones Industrial Average ETF Trust

FANG

ILMN

NXPI

PLTR

VRTX

Select Sector SPDR-Consumer Discretionary

YUMC

Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?

On Friday, the FDA warned against using Hologic Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) BioZorb Marker products and urged healthcare facilities to return all unused lots.
This follows Hologic&#8217;s voluntary <a target="_blank" href="https://www.hologic.com/biozorb-3d-bioabsorbable-marker-important-recall-information" rel="noreferrer noopener">recall</a> of the BioZorb Marker and BioZorb LP Marker, implantable devices intended for marking sites in soft tissues like breast tissue.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41319059/hologic-adds-gynesonics-sonata-system-in-350m-acquisition-to-boost-fibroid-treatmen" rel="noreferrer noopener">Hologic Adds Gynesonics&#8217; Sonata System In $350M Acquisition To Boost Fibroid Treatments</a>
The recall comes in response to reports of serious adverse events in patients, including pain, infection, and device migration, among others.
The BioZorb Marker, introduced as a radiographic tool for marking soft tissue sites, consists of a dissolvable plastic component and a permanent titanium metal part.
While it helps mark areas for future medical procedures, the FDA emphasized it is not approved to fill tissue space, enhance cosmetic results, or serve as a radiation treatment marker.
In February, Hologic <a target="_blank" href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#:~:text=The%20FDA%20has%20received%20reports,from%20feeling%20the%20device%20in" rel="noreferrer noopener">alerted</a> healthcare providers about potential risks, but the recent recall expands on that, mandating the return of all unused BioZorb devices as a preventive action.
The FDA and Hologic outlined essential steps for healthcare providers, recommending against implanting BioZorb Markers, quarantining existing devices, and discussing associated risks with patients who already have the implant.
This guidance aims to ensure patients&#8217; safety, given the documented complications of BioZorb devices in breast tissue, which range from minor rashes to severe issues such as device erosion through the skin.
Since BioZorb&#8217;s launch in 2015, approximately 91,531 units have been sold, with 399 complaints reported as of October 2024.
Among these, 188 cases were linked to adverse effects.
Price Action: HOLX stock is down 0.95% at $80.14 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41552265/johnson-johnsons-blockbuster-drug-tremfya-clears-plaque-psoriasis-with-lesions-covering-bodys-sma" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body&#8217;s Smaller Areas</a>.</li>
</ul>

Health Care

General

Hologic Recalls Soft Tissue Marker Device BioZorb, FDA Issues Warning After Almost 400 Complaints

<a href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#:~:text=The%20FDA%20has%20received%20reports,from%20feeling%20the%20device%20in">https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#:~:text=The%20FDA%20has%20received%20reports,from%20feeling%20the%20device%20in</a>
&nbsp;
Date Issued: October 25, 2024
The U.S. Food and Drug Administration (FDA) is alerting consumers, health care providers and health care facilities not to use BioZorb Markers and BioZorb LP Markers (hereafter referred to simply as BioZorb Markers) by Hologic Inc.
On October 25, 2024, Hologic <a href="https://www.hologic.com/biozorb-3d-bioabsorbable-marker-important-recall-information">announced</a><a href="http://www.fda.gov/about-fda/website-policies/website-disclaimer">External Link Disclaimer</a> a voluntary recall for removal of all lots of unused BioZorb Markers. The recall is due to reports of serious adverse events occurring in patients who had the devices implanted in breast tissue.
The FDA is issuing this communication to help ensure you are aware of the manufacturer&#39;s most recent recall notice and the recommended actions.
<h2>Recommendations for Patients with a BioZorb Marker and their Caregivers</h2>
<ul>
<li>If you experience any adverse events with your BioZorb Marker, please contact your health care provider.</li>
<li>There is no need to have the device removed from your body (explanted) unless advised by your health care provider.</li>
<li>If your provider is planning radiation therapy treatments, discuss the possible risks with your provider. The FDA has not cleared or approved the use of BioZorb Marker as a marker for radiation treatment.</li>
<li><a href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#report">Report any problems or complications</a> with your BioZorb Marker to the FDA.</li>
</ul>
<h2>Recommendations for Health Care Providers and Facilities</h2>
<ul>
<li>Do not implant BioZorb Markers.</li>
<li>Quarantine and return all lots of unused BioZorb Markers to Hologic.</li>
<li>Review and discuss the Recommendations for Patients above with your patients who have a BioZorb Marker.</li>
<li>Be aware of reports of serious adverse events following the placement of BioZorb Marker devices in breast tissue.</li>
<li>Continue to monitor patients who have an implanted BioZorb Marker for signs of any adverse events.</li>
<li>Be aware the FDA has not cleared or approved the use of BioZorb Markers to fill space in the tissue or to improve cosmetic outcomes after procedures, or as a marker for radiation treatment.</li>
<li><a href="https://www.fda.gov/medical-devices/safety-communications/update-do-not-use-biozorb-marker-implantable-radiographic-marker-devices-fda-safety-communication#report">Report any problems or complications</a> your patients experience following the placement of BioZorb Marker devices to the FDA.</li>
</ul>
<h2>Device Description</h2>
BioZorb Markers are implantable devices used in soft tissue sites, including breast tissue. BioZorb Markers have two parts: a plastic component that is intended to be dissolved completely in the patient&#39;s body in one year or longer, and a titanium metal component that is permanent.
The BioZorb Marker is indicated for radiographic marking of sites in soft tissue. In addition, the BioZorb Marker is indicated in situations where the soft tissue site needs to be marked for future medical procedures.
The BioZorb Marker is not indicated to improve cosmetic outcomes after procedures, fill space in the tissue, or to be a marker for radiation treatment.
<h2>Risks Associated with BioZorb Marker in Breast Tissue</h2>
Reported complications and adverse events with BioZorb Marker that include serious injuries are:
<ul>
<li>Pain</li>
<li>Infection</li>
<li>Rash</li>
<li>Device migration (moving out of position)</li>
<li>Device erosion (breaking through the skin)</li>
<li>Seroma (fluid buildup)</li>
<li>Discomfort</li>
<li>Other complications from feeling the device in the breast</li>
</ul>
In some instances, additional medical treatment, including having the device removed from the body (explantation), was needed.
<h2>FDA Actions</h2>
The FDA will continue to work with Hologic to monitor reports of problems with BioZorb Markers, including issues that may develop over time.
The FDA will continue to keep the public informed if significant new information becomes available.

Biotech

FDA In Safety Communication Says Do Not Use BioZorb Marker Implantable Radiographic Marker Devices; Hologic Recall Due To Reports Of Serious Adverse Events Occurring In Patients Who Had BioZorb Marker Devices Implanted In Breast Tissue

Needham analyst Mike Matson reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Buy and maintains $90 price target.

Reiteration

Needham Reiterates Buy on Hologic, Maintains $90 Price Target

On Monday, Hologic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) agreed to acquire&nbsp;&nbsp;Gynesonics, Inc. for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41310959/hologic-to-acquire-gynesonics-developer-of-minimally-invasive-solutions-for-womens-health" rel="noreferrer noopener">approximately $350 million</a>.
Gynesonics is a privately held medical device company that develops minimally invasive solutions for women&#8217;s health.
California-based Gynesonics develops and sells the Sonata System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.
The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39534064/womens-health-focused-hologic-has-significant-capacity-for-expansion-via-m-a-bullis" rel="noreferrer noopener">Women&#8217;s Health-Focused Hologic Has Significant Capacity For Expansion Via M&amp;A, Bullish Analyst Says</a>.
William Blair writes that Sonata System&#8217;s approach differs from Hologic&#8217;s Acessa device/ procedure, which delivers imaging and radiofrequency heat through two small abdominal incisions.
Hologic&#8217;s MyoSure device/procedure is also a solution for fibroid removal, though this is done through tissue removal rather than tissue ablation. &#8220;We believe that while there could become overlap amongst these products, having different solutions in Hologic&#8217;s product suite should allow for greater adoption,&#8221; the analyst writes.
Given the target&#8217;s profile, William Blair analyst says it is unlikely that the deal will significantly impact Hologic&#8217;s objective of maintaining operating margins in the low-30% range.
Hologic is scheduled to report fiscal fourth-quarter<a target="_blank" href="https://www.benzinga.com//node/41183593" rel="noreferrer noopener"> earnings in early November.</a>
As per data from Benzinga Pro, analysts expect adjusted EPS of $1.01 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">revenues of $977.05 million</a>.
The analyst adds that revenue and earnings forecasts and consensus estimates have decreased in the past month as the company signals a more cautious stance on non-core elements like net interest expense.
The company is well-positioned to achieve mid-single-digit organic revenue growth, with earnings growth projected to outpace that in the high-single- to low-double-digit percentage range over time.
Several factors could drive earnings within this expected range, and shares are trading at a fair multiple of just under 19 times 2025 earnings.
The analyst reiterates <a target="_blank" href="https://www.benzinga.com/quote/HOLX/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: HOLX stock is up 1.54% at $81.04 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41317937/qualcomm-set-for-50-surge-in-snapdragon-8-gen-4-shipments-by-late-2024-analyst-pred" target="_blank" rel="noreferrer noopener">Qualcomm Set For 50% Surge In Snapdragon 8 Gen 4 Shipments By Late 2024, Analyst Predicts</a>.</li>
</ul>

Analyst Color

Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatments

Hologic To Acquire Women's Health Medical Device Co. Gynesonics For ~$350M

Leerink Partners analyst Puneet Souda maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $95 to $90.

Leerink Partners Maintains Outperform on Hologic, Lowers Price Target to $90

10 analysts have shared their evaluations of Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Hologic, presenting an average target of $86.6, a high estimate of $95.00, and a low estimate of $78.00. Observing a 0.7% increase, the current average has risen from the previous average price target of $86.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728065025_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Hologic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$82.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Hologic's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>Unveiling the Story Behind Hologic</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Hologic: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Hologic's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.74%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin excels beyond industry benchmarks, reaching 19.23%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hologic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hologic's ROA stands out, surpassing industry averages. With an impressive ROA of 2.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Hologic's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Hologic: Insights From 10 Financial Analysts

Mizuho analyst Anthony Petrone maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and raises the price target from $85 to $90.

Mizuho Maintains Outperform on Hologic, Raises Price Target to $90

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – QuinStreet&nbsp;(QNST)&nbsp;u...

Closing Bell Movers: Palantir jumps 13% after results

Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript

Hologic ( ($HOLX) ) has released its Q4 earnings. Here is a breakdown of the information Hologic presented to its investors. Hologic, Inc. is a med...

Hologic Reports Robust Q4 2024 Financial Growth

Analyst Michael Matson from Needham reiterated a Buy rating on Hologic (HOLX – Research Report) and keeping the price target at $90.00. Michael Mat...

Hologic's Strong Performance and Future Growth Prospects Justify Buy Rating

In a report released yesterday, Conor McNamara from RBC Capital maintained a Hold rating on Hologic (HOLX – Research Report), with a price target o...

RBC Capital Reaffirms Their Hold Rating on Hologic (HOLX)

Mizuho analyst Anthony Petrone lowered the firm's price target on Hologic (HOLX) to $87 from $90 and keeps an Outperform rating on the shares. The ...

Hologic price target lowered to $87 from $90 at Mizuho

Raymond James raised the firm's price target on Hologic (HOLX) to $95 from $93 and keeps an Outperform rating on the shares. Hologic reported an in...

Hologic price target raised to $95 from $93 at Raymond James

RBC Capital raised the firm's price target on Hologic (HOLX) to $89 from $86 and keeps a Sector Perform rating on the shares after its Q4 results a...

Hologic price target raised to $89 from $86 at RBC Capital

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $90.00. Punee...

Hologic's Strategic Advancements and Robust Market Position Earns 'Buy' Rating Despite Conservative Outlook

The latest update is out from Hologic ( ($HOLX) ). Hologic, Inc.'s Compensation Committee has approved new Performance Stock Unit Award Agreements ...

Comments

Hologic

ニュース

最新ニュース Hologic (NASDAQ:HOLX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル